Overview

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia
Phase:
Phase 2
Details
Lead Sponsor:
Kastle Therapeutics, LLC
Collaborator:
Ionis Pharmaceuticals, Inc.
Treatments:
Mipomersen